Přihlásit se Zaregistrujte se zdarma

Zisková marže společnosti SinoMab BioScience

Jaká je hodnota metriky Zisková marže společnosti SinoMab BioScience?

Hodnota metriky Zisková marže společnosti SinoMab BioScience Limited je -5,537.81%

Jaká je definice metriky Zisková marže?



Zisková marže (Profit margin) je procento čistého zisku z celkových tržeb.

Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.

Zisková marže společností v sektoru Health Care sektor na HKSE ve srovnání se společností SinoMab BioScience

Čemu se věnuje společnost SinoMab BioScience?

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Firmy s metrikou zisková marže podobnou společnosti SinoMab BioScience



  • Hodnota metriky Zisková marže společnosti Touchpoint je -5,708.79%
  • Hodnota metriky Zisková marže společnosti Real Luck je -5,700.00%
  • Hodnota metriky Zisková marže společnosti Malachite Resources je -5,693.33%
  • Hodnota metriky Zisková marže společnosti Ardea Resources je -5,653.33%
  • Hodnota metriky Zisková marže společnosti King Island Scheelite je -5,594.26%
  • Hodnota metriky Zisková marže společnosti Vango Mining je -5,538.46%
  • Hodnota metriky Zisková marže společnosti SinoMab BioScience je -5,537.81%
  • Hodnota metriky Zisková marže společnosti RAPT Therapeutics je -5,490.37%
  • Hodnota metriky Zisková marže společnosti Graphene Manufacturing je -5,482.35%
  • Hodnota metriky Zisková marže společnosti Energous je -5,474.06%
  • Hodnota metriky Zisková marže společnosti Tanga Resources je -5,428.57%
  • Hodnota metriky Zisková marže společnosti Zonetail je -5,421.05%
  • Hodnota metriky Zisková marže společnosti Kopore Metals je -5,391.30%